BIOLASE (NASDAQ:BIOL) PT Lowered to $5.00 at Maxim Group

BIOLASE (NASDAQ:BIOLGet Rating) had its price target reduced by Maxim Group from $10.00 to $5.00 in a research note released on Friday, The Fly reports.

Separately, StockNews.com started coverage on BIOLASE in a research report on Wednesday, November 9th. They set a sell rating on the stock.

BIOLASE Stock Up 13.4 %

BIOL opened at $1.86 on Friday. The business’s 50-day simple moving average is $2.35 and its 200-day simple moving average is $4.49. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.99 and a current ratio of 3.17. BIOLASE has a one year low of $1.40 and a one year high of $13.83. The stock has a market capitalization of $12.75 million, a P/E ratio of -0.52 and a beta of 1.45.

Hedge Funds Weigh In On BIOLASE

Several institutional investors have recently added to or reduced their stakes in BIOL. Commonwealth Equity Services LLC increased its position in BIOLASE by 117.8% in the 1st quarter. Commonwealth Equity Services LLC now owns 101,046 shares of the medical technology company’s stock valued at $35,000 after acquiring an additional 54,650 shares during the period. Essex Investment Management Co. LLC increased its position in BIOLASE by 2.5% in the 1st quarter. Essex Investment Management Co. LLC now owns 1,621,992 shares of the medical technology company’s stock valued at $573,000 after acquiring an additional 39,281 shares during the period. State Street Corp increased its position in BIOLASE by 4.5% in the 1st quarter. State Street Corp now owns 436,076 shares of the medical technology company’s stock valued at $154,000 after acquiring an additional 18,682 shares during the period. Capital Wealth Alliance LLC acquired a new position in BIOLASE in the 2nd quarter valued at about $51,000. Finally, Citadel Advisors LLC acquired a new position in BIOLASE in the 2nd quarter valued at about $118,000. Institutional investors and hedge funds own 21.21% of the company’s stock.

BIOLASE Company Profile

(Get Rating)

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications.

Read More

The Fly logo

Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.